
IndraLab
Statements
reach
"This rebound, characterized by marked induction of GTP-bound forms of wild-type HRAS and KRAS, which was otherwise abrogated by the knockdown of HRAS and NRAS, leads to MAPK pathway activation in a KRAS G12C-independent way, suggesting that it can not be overcome by escalating the dosage of KRAS G12C inhibitors."
reach
"This therapeutic concept could also be extended to NRas/BRaf-driven melanomas, BRaf-driven pediatric brain tumors, PTEN-driven prostate cancers and KRas-driven NSCLCs that are all Ras/Raf driven malignancies that rely on autophagy for survival (Lee et al., 2019; Mulcahy Levy et al., 2017; Santanam et al., 2016; Strohecker et al., 2013; Xie et al., 2015)."